The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma.
Calliditas inches closer to full approval for IgA nephropathy drug – Pharmaceutical Technology
IgA nephropathy is a kidney disorder that causes inflammation. The US Food and Drug Administration (FDA) has granted Calliditas Therapeutics’ immunoglobulin A (IgA) nephropathy (IgAN)
August 21, 2023